Accelerated Underwriting – Get on the Right Track
Seeing the many different projects being pursued by direct companies is one of the most interesting aspects of working in reinsurance. Just recently I’ve noticed how many life carriers are going down the Accelerated Underwriting (AU) route.
Drug Abuse Mortality in the Insured Population
Population data show that drug-related mortality rates have more than doubled since the beginning of the century. This statistic is troubling enough as it is, but it hides the fact that almost all the increase is due to opioids, which account for just over half of the deaths.
Personal genomic testing (PGT): The consumer and the Life Insurance Industry
The life insurance industry is being challenged to respond to the new reality of democratized access to personal genomic data against the backdrop of consumer and regulatory concerns around data privacy, consumer equity and genetic determinism, on the one hand, and life insurers’ concerns about information asymmetry during the underwriting process, on the other.
UPDATE: Debunking the Myths: the Facts about Cotinine
This popular post from 2012 has been updated with recent research.
Genetics and Life Insurance - A View into the Microscope of Regulation
The use of genetic information for life, disability, critical illness and long-term care insurance is likely to increase in relevance. This report represents an attempt to understand key aspects of genetics, as well as limitations and controversies of its utilization in life insurance.
SCOR Housecalls: A Closer Look at Screening Tests
Inevitably we see cases in underwriting where the applicant has had an abnormality in a screening test and the follow-up testing is in progress or has been inconclusive. Those individuals are often postponed, while other applicants with similar characteristics who are not undergoing screening tests sail through the underwriting process without a second thought.
Are Functional Neurological Symptoms the “Great Deceivers”?
For insurers, neurological symptoms that remain unexplained by conventional medical investigations are a source of anxiety. While there is extensive guidance on managing risk in specific diagnoses, there is little when the patients’ experiences do not have a formal label.
Screening and Non-Small-Cell Lung Cancer
This article reviews key advances in the management of non-small-cell lung cancer and the clinical gains in outcomes as well as the ability to deliver personalized cancer treatment.